Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Merck Sharpe and Dohme reports positive Janumet trial data

Merck Sharpe and Dohme reports positive Janumet trial data

30th June 2010

Merck Sharpe and Dohme has reported positive findings from a new comparative clinical trial of Janumet, its treatment for type 2 diabetes.

The pharmaceutical company conducted a 32-week study involving 517 patients in order to gauge its efficacy in improving glycemic control when compared to pioglitazone.

It was found that the Merck Sharpe and Dohme drug delivered a range of benefits compared to the alternative treatment, including greater blood sugar reductions and weight loss, as well as a lower risk of edema, swelling and gastrointestinal events.

The treatment combines the effects of sitagliptin and metformin and is indicated as an adjunct to diet and exercise.

Dr Barry Goldstein, vice-president of clinical research at Merck Research Laboratories, said: “These findings support the use of combination therapy with Janumet for appropriate patients upon diagnosis with type 2 diabetes.”

Earlier this week, Merck Sharpe and Dohme was granted a recommendation from European Medicines Agency’s Committee for Medicinal Products for Human Use for Brinavess, its new treatment for atrial fibrillation.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.